Various vaccines are being used around the world to protect against Code 19, and new data on the modern vaccine have recently been released.
According to an international website, a recent study found that the effectiveness of modern vaccine codes decreases after several months.
This is stated in the new data released by Moderna.
The company’s data showed that people who were given the first dose of the vaccine 13 months ago were more likely to develop a breakthrough infection than those who took the first dose in eight months.
The data show that the protection from vaccination is reduced by 36% in a year. This data was collected in the third phase of a clinical trial conducted by Moderna.
The vaccine was approved for use in the United States on the basis of the same clinical trial, and in its early stages, participants were given the company’s MRNA vaccine or placebo.
The results found that those involved in the trial had a 36% lower chance of developing a breakthrough infection.
The trial data revealed breakthrough cases in 88 of the 11,431 volunteers who were vaccinated between December 2020 and March 2021.
In comparison, 162 of the 14,746 people who were vaccinated between July and October 2020 were diagnosed with breakthrough cases.
Moderna CEO Stanf Bensel said in a statement that the results showed that people who had been vaccinated last year had a higher risk of developing a breakthrough infection than those who had been vaccinated in recent months.
He said that this indicates a decrease in the effectiveness of the vaccine and supports the need for booster doses to maintain the highest level of protection.
The US Food and Drug Administration’s (FDA) advisory committee is meeting on September 17 to review the available evidence and decide whether to approve the booster dose.